The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Accelerating Biological Understanding and Therapeutic Translation for Parkinson’s Disease Program, 2023SUPPLEMENT | Reducing Expression of the Gene for Alpha-synuclein in an Advanced Preclinical Model of Parkinson’s Disease
Study Rationale: Numerous genetic studies of families with parkinsonism and mutations in the alpha-synuclein gene suggest that an excess of alpha-synuclein leads to neurodegeneration and Parkinson’s...
-
Lysosomal Biomarkers Program, 2023Developing a Targeted Proteomic Test to Monitor Blood Samples for Lysosomal Signatures of Parkinson’s Disease
Study Rationale: Lysosomes are structures that help clear cells of molecular debris, and lysosomal dysfunction has been linked to neurodegeneration in Parkinson’s disease (PD). In this study, we will...
-
Lysosomal Biomarkers Program, 2023Measurement of Neuronal Extracellular Vesicles as a Blood-based Biomarker for Lysosomal Function
Study Rationale: Parkinson’s disease (PD) is associated with the aggregation of toxic proteins, a buildup due partly to the reduced ability of lysosomes to degrade these proteins. Improving lysosome...
-
Lysosomal Biomarkers Program, 2023Development of Autophagy-lysosome Biomarkers for Parkinson’s Disease Using Stem Cell-derived Neurons and Biofluids
Study Rationale: Genetic, molecular, and pathological studies have highlighted the role of dysfunctional mechanisms for clearing cellular debris — called autophagy-lysosome pathways — in the...
-
Accelerating Biological Understanding and Therapeutic Translation for Parkinson’s Disease Program, 2023Evaluating the Impact of LRRK2 Mutation on Lysosomal Function in Macrophages
Study Rationale: Mutations in LRRK2 are associated with inherited forms of Parkinson’s disease (PD). LRRK2 is a lysosomal protein that is produced in immune cells, such as macrophages. These cells are...
-
Accelerating Biological Understanding and Therapeutic Translation for Parkinson’s Disease Program, 2023Targeting the Blood-brain Immune Axis to Prevent Progression of Parkinson’s Disease
Study Rationale: Recent studies suggest that the barrier that separates the brain from the rest of the body, including the blood, might become dysfunctional over the course of Parkinson’s disease (PD)...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.